Nexvet Biopharma plcWednesday, 11 March 2015
ByrneWallace acted for Nexvet Biopharma plc, a clinical-stage biopharmaceutical company focusing on companion animals, in relation to the successful closing of its fully underwritten US$40 million initial public offering. Nexvet’s ordinary shares are listed on the NASDAQ Global Market under the ticker symbol “NVET”.
ByrneWallace also acted for Nexvet in relation to a complex corporate re-organisation whereby Nexvet Biopharma plc became the parent company of Nexvet Australia Pty Ltd which was completed in September 2014.
The transaction was handled by Colin Sainsbury (Partner), Oisín McLoughlin (Associate) and Laura Greene (Solicitor).